Bangladesh vs Guyana: HIV/AIDS deaths averted by antiretroviral therapy
Bangladesh
479.38 deaths
in 2024
Guyana
512.85 deaths
in 2024
Bangladesh rank
94th
Guyana rank
93rd
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bangladesh
- Guyana
How they compare
Guyana currently reports 512.85 deaths against 479.38 deaths in Bangladesh, a difference of 33.47 deaths.
That makes Guyana's figure about 1.1 times Bangladesh's.
Across all 35 years both countries report, Guyana has been ahead every year.
Bangladesh ranks 94th and Guyana ranks 93rd of 157 countries.
Guyana has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bangladesh | Guyana | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 13.01 deaths | 139.91 deaths | 126.9 deaths | Guyana |
| 2010s | 178.72 deaths | 424.71 deaths | 245.98 deaths | Guyana |
| 2020s | 388.8 deaths | 494.78 deaths | 105.98 deaths | Guyana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bangladesh or Guyana?
- Guyana, at 512.85 deaths against 479.38 deaths in Bangladesh as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bangladesh and Guyana?
- 33.47 deaths, with Guyana ahead.
- How many years of comparable data are there for Bangladesh and Guyana?
- 35 years are reported by both, from 1990 to 2024.
- How do Bangladesh and Guyana rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bangladesh ranks 94th and Guyana ranks 93rd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.